Press Room

Event

DDF - 15th Global Drug Delivery & Formulation Summit

Start
Tuesday, May 21, 2024
End
Thursday, May 23, 2024
Location: Berlin, Germany
Booth Number: Table # 16
DDF_Hovione_2024

Hovione will be exhibiting at the Global DDF Summit, the premier drug delivery, formulation and device development event from May 21-23 in Berlin. 

Don’t miss the chance to speak with our experts – Table No. 16 – and learn how our extensive knowledge and experience can support your project from early stages of development to commercialization.

schedule a meeting
https://go.hovione.com/l/47122/2014-08-06/9grc

 

 

 

 

On May 22, don’t miss our Technology & Innovation session 

Manufacturing Amorphous Solid Dispersions for Continuous Direct Compression: Streamlining End-to-End Formulation and Process Development

 

This presentation will provide an end-to-end overview of an amorphous solid dispersion (ASD) development approach focusing not only on selecting the best excipients (including alternative excipients to broaden the formulation landscape) but also how to convert it into a commercially viable process as a final oral dosage form by Continuous Direct Compression. Using a streamlined approach and proprietary technologies, an overview of how to expedite the screening phase and process development with minimal API requirements will be given. This not only shortens the time to Phase I/IND by accelerating formulation and process development but also improves supply chain flexibility and opens new possibilities for Lifecycle Management. To deliver a successful ASD-based oral dosage form by Continuous Direct Compression, the following aspects must be considered: 1) high-throughput screening, 2) digital twins and scale-up models, and 3) integrated ASD and tablet formulation / process development. Hovione case studies on enabling Continuous Direct Compression of ASDs will be discussed.

 

Key learnings:

  • Unleashing full potential of ASDs requires integrated optimization of formulations and processes, leveraging integrated high throughput formulation platforms (ASD-HIPROS) to reduce time to Phase I/IND.
  • Engineered Spray Dried powders are amenable to Continuous Direct Compression, which greatly simplifies drug product process trains and improves supply chain flexibility / Lifecycle Management options.

 

Schedule a meeting with our experts and learn how we can maximize the potential of your ASD development and streamline your drug product processes.

 
Webinar Series Spray Drying Speakers - Ines Ramos | Hovione
 
Webinar Series Spray Drying Speakers - Pedro Monteiro | Hovione
Inês Ramos, Ph.D.

R&D Manager

Oral Drug Product Development - Formulation Group		 Pedro Monteiro, M.Sc. 

R&D Senior Scientist 

Oral Drug Product Development - Formulation Group

 

Find more about DDF 

 



Get to know more about ASD-HIPROS, the most advanced and accurate screening platform able to identify the most efficient and stable Amorphous Solid Dispersion formulations by Spray Drying. 

Get to know more about Continuous Tableting at Hovione.

 

 

Also in the Press Room

See All

Twenty companies presented at the annual kickoff to DCAT Week. The Drug, Chemical & Associated Technologies Association (DCAT) opened DCAT Week 2026 with its Member Company Announcement Forum. The kickoff to the annual event in New York City, underway from March 23–26, 2026, showcased 20 companies. These were selected based on their announcements’ “news priority, criticality, and interest” to DCAT member companies. The following is a summary of highlights from the presentations, supplemented by additional information provided by some of the companies. (...) Hovione Hovione’s Vice President of Technical Operations for the Americas, David Basile, delivered the company’s Member Company Announcement Forum presentation. Basile will be speaking exclusively with Contract Pharma during DCAT Week, so check back for more on Hovione’s latest.   Read the full article at ContractPharma.com    

Press Clipping
Contract Pharma, 23 March 2026

DCAT Member Company Announcement Forum 2026: An Inside Look

Mar 23, 2026

With more than six decades of experience in pharmaceutical development and manufacturing, Hovione is an international CDMO offering a comprehensive range of services for New Molecular Entities (NMEs), including drug substances, intermediates, and drug products. The company also supplies niche generic APIs and delivers advanced technologies supporting multiple drug delivery platforms, including oral, injectable, inhalation, and topical formulations.  Today, Hovione employs 2,500 people worldwide and operates 900 m3 of manufacturing capacity across four sites in Europe, the U.S. and Asia. Japan has played an important role in the company’s global strategy since its early years. Initial export activities were followed in 2017 by the establishment of a Japanese subsidiary in Osaka.   Read the full article in Japanese at Yakuji.co.jp Read the article translated in English  

Press Clipping
Yakuji Nippo Magazine, 13 March 2026

International CDMO strengthens its presence in Japan: from active pharmaceutical ingredients to formulations, all at the same location

Mar 13, 2026

In an interview with Executiva, a portuguese media outlet focused on women´s leadership, Diane Villax, co-founder and long-standing leader of Hovione, reflects on her journey and the company’s development over more than six decades. Diane Villax’s career began at a time when few women worked outside the home. At 19, she joined a trading company as a foreign languages correspondent, where she developed essential business skills — including commercial correspondence, banking and export procedures — that later proved instrumental in helping her husband, Ivan Villax, establish Hovione in 1959. From its earliest days operating in the family home in Lisbon, Hovione adopted an international outlook. The company’s first major customers were in Japan, setting demanding quality standards that helped shape its long-term position in global markets. Over the following decades, Hovione expanded its footprint with the construction of its first manufacturing site in Loures (1969), followed by expansion to Macau (1986), the United States (New Jersey, early 2000s) and Ireland (Cork). The company grew into a global organization with more than 2,500 employees — including over 300 scientists — and a reputation as a preferred supplier to leading pharmaceutical companies worldwide. Throughout the interview, Diane highlights the values that have guided the company’s development: a commitment to excellence, a strong work ethic, and a focus on quality and long-term relationships. Although she did not have formal business training, she learned “on the job” and brought discipline, precision and structure to her role — particularly in the company’s early financial and administrative leadership. Now in her nineties and an active member of Hovione’s Board of Directors, Diane Villax remains engaged with the company’s evolution and governance, reflecting a continued commitment to its long-term development. Her story reflects entrepreneurial drive, resilience and long-term leadership — and offers insight into the values that have shaped Hovione’s trajectory for more than six decades. Read the full interview at Executiva.pt (in portuguese).    

Article
Executiva, 23 February 2026

Hovione’s Diane Villax: “I was not brought up to be a business woman”

Feb 23, 2026

Also in Events

See All